259 related articles for article (PubMed ID: 22361433)
1. Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting.
Shum AM; Mahendradatta T; Taylor RJ; Painter AB; Moore MM; Tsoli M; Tan TC; Clarke SJ; Robertson GR; Polly P
Aging (Albany NY); 2012 Feb; 4(2):133-43. PubMed ID: 22361433
[TBL] [Abstract][Full Text] [Related]
2. MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.
Judge SM; Deyhle MR; Neyroud D; Nosacka RL; D'Lugos AC; Cameron ME; Vohra RS; Smuder AJ; Roberts BM; Callaway CS; Underwood PW; Chrzanowski SM; Batra A; Murphy ME; Heaven JD; Walter GA; Trevino JG; Judge AR
Cancer Res; 2020 May; 80(9):1861-1874. PubMed ID: 32132110
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
4. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
5. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.
Aulino P; Berardi E; Cardillo VM; Rizzuto E; Perniconi B; Ramina C; Padula F; Spugnini EP; Baldi A; Faiola F; Adamo S; Coletti D
BMC Cancer; 2010 Jul; 10():363. PubMed ID: 20615237
[TBL] [Abstract][Full Text] [Related]
6. Regulation of skeletal muscle sarcomere integrity and postnatal muscle function by Mef2c.
Potthoff MJ; Arnold MA; McAnally J; Richardson JA; Bassel-Duby R; Olson EN
Mol Cell Biol; 2007 Dec; 27(23):8143-51. PubMed ID: 17875930
[TBL] [Abstract][Full Text] [Related]
7. Myostatin is a novel tumoral factor that induces cancer cachexia.
Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M
Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.
Tseng YC; Kulp SK; Lai IL; Hsu EC; He WA; Frankhouser DE; Yan PS; Mo X; Bloomston M; Lesinski GB; Marcucci G; Guttridge DC; Bekaii-Saab T; Chen CS
J Natl Cancer Inst; 2015 Dec; 107(12):djv274. PubMed ID: 26464423
[TBL] [Abstract][Full Text] [Related]
9. Muscle oxidative capacity during IL-6-dependent cancer cachexia.
White JP; Baltgalvis KA; Puppa MJ; Sato S; Baynes JW; Carson JA
Am J Physiol Regul Integr Comp Physiol; 2011 Feb; 300(2):R201-11. PubMed ID: 21148472
[TBL] [Abstract][Full Text] [Related]
10. NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia.
He WA; Berardi E; Cardillo VM; Acharyya S; Aulino P; Thomas-Ahner J; Wang J; Bloomston M; Muscarella P; Nau P; Shah N; Butchbach ME; Ladner K; Adamo S; Rudnicki MA; Keller C; Coletti D; Montanaro F; Guttridge DC
J Clin Invest; 2013 Nov; 123(11):4821-35. PubMed ID: 24084740
[TBL] [Abstract][Full Text] [Related]
11. Type I muscle atrophy caused by microgravity-induced decrease of myocyte enhancer factor 2C (MEF2C) protein expression.
Yamakuchi M; Higuchi I; Masuda S; Ohira Y; Kubo T; Kato Y; Maruyama I; Kitajima I
FEBS Lett; 2000 Jul; 477(1-2):135-40. PubMed ID: 10899324
[TBL] [Abstract][Full Text] [Related]
12. Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response.
Guo D; Wang C; Wang Q; Qiao Z; Tang H
Oncotarget; 2017 Jun; 8(24):39640-39648. PubMed ID: 28489606
[TBL] [Abstract][Full Text] [Related]
13. Metalloproteinase expression is altered in cardiac and skeletal muscle in cancer cachexia.
Devine RD; Bicer S; Reiser PJ; Velten M; Wold LE
Am J Physiol Heart Circ Physiol; 2015 Aug; 309(4):H685-91. PubMed ID: 26092976
[TBL] [Abstract][Full Text] [Related]
14. Colon 26 adenocarcinoma (C26)-induced cancer cachexia impairs skeletal muscle mitochondrial function and content.
Neyroud D; Nosacka RL; Judge AR; Hepple RT
J Muscle Res Cell Motil; 2019 Mar; 40(1):59-65. PubMed ID: 30945134
[TBL] [Abstract][Full Text] [Related]
15. A standardized herbal combination of Astragalus membranaceus and Paeonia japonica, protects against muscle atrophy in a C26 colon cancer cachexia mouse model.
Lee SB; Lee JS; Moon SO; Lee HD; Yoon YS; Son CG
J Ethnopharmacol; 2021 Mar; 267():113470. PubMed ID: 33068652
[TBL] [Abstract][Full Text] [Related]
16. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.
Bonetto A; Aydogdu T; Kunzevitzky N; Guttridge DC; Khuri S; Koniaris LG; Zimmers TA
PLoS One; 2011; 6(7):e22538. PubMed ID: 21799891
[TBL] [Abstract][Full Text] [Related]
17. Myosin heavy chain is not selectively decreased in murine cancer cachexia.
Cosper PF; Leinwand LA
Int J Cancer; 2012 Jun; 130(11):2722-7. PubMed ID: 21796617
[TBL] [Abstract][Full Text] [Related]
18. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.
White JP; Puppa MJ; Gao S; Sato S; Welle SL; Carson JA
Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1042-52. PubMed ID: 23531613
[TBL] [Abstract][Full Text] [Related]
19. Comparative molecular analysis of early and late cancer cachexia-induced muscle wasting in mouse models.
Sun R; Zhang S; Lu X; Hu W; Lou N; Zhao Y; Zhou J; Zhang X; Yang H
Oncol Rep; 2016 Dec; 36(6):3291-3302. PubMed ID: 27748895
[TBL] [Abstract][Full Text] [Related]
20. Increased hypoxia-inducible factor-1α in striated muscle of tumor-bearing mice.
Devine RD; Bicer S; Reiser PJ; Wold LE
Am J Physiol Heart Circ Physiol; 2017 Jun; 312(6):H1154-H1162. PubMed ID: 28341633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
